An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03

被引：0

作者：

Krop, Ian E.

Wildiers, Hans

Hurvitz, Sara A.

Cortes, Javier

Im, Seock-Ah

Iwata, Hiroji

Andre, Fabrice

Saura, Cristina

Modi, Shanu

Kim, Sung-Bae

Egorov, Anton

Mathias, Elton

Cathcart, Jillian

Cagnazzo, Antonio

Cheng, Yingkai

Park, Yeon Hee

机构：

[1] Yale Canc Ctr, New Haven, CT USA

[2] Univ Hosp Leuven, Leuven, CA, Belgium

[3] UCLA Hematol Oncol, Los Angeles, CA USA

[4] Int Breast Canc Ctr IBCC, Quironsalud Grp, Pangaea Oncol, Barcelona, Spain

[5] Seoul Natl Univ Hosp, Seoul, South Korea

[6] Aichi Canc Ctr Hosp, Aichi, Japan

[7] Inst Gustave Roussy, Villejuif, France

[8] Vall Hebron Univ Hosp, Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Univ Ulsan Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea

[11] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[12] Samsung Med Ctr, Seoul, South Korea

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1006

引用

页数：1